EORTC new drug development office coordinating and monitoring programme for phase I and II trials with new anticancer agents-Reference-Cited by-同舟云学术

EORTC new drug development office coordinating and monitoring programme for phase I and II trials with new anticancer agents

Published:1991-09 Issue:9 Volume:27 Page:1162-1168
ISSN:0277-5379
Container-title:European Journal of Cancer and Clinical Oncology
language:en
Short-container-title:European Journal of Cancer and Clinical Oncology

Author:

Schwartsmann G.,Wanders J.,Koier I.J.,Franklin H.R.,Dalesio O.,Hornstra H.W.,van Glabbeke M.,Renard J.,Van Oosterom A.T.,Kaye S.B.,Pinedo H.M.

Publisher

Elsevier BV

Subject

Oncology

Reference22 articles.

1. Development of new anticancer drugs;Pinedo;Med Oncol Tumor Pharmacother,1986

2. The main steps in the development of new anticancer agents;Schwartsmann;Radiother Oncol,1988

3. Good clinical practice for trials on medicinal products in the European Community, III/3976/88-EN;Commission of the European Communities;The rules governing medicinal products in the European Community,1989

4. Approach to phase I trials in cancer patients;Rozencweig,1982

5. Animal toxicology for early clinical trials;Rozencweig;Cancer Clin Trials,1981

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The dual effect of curcumin nanoparticles encapsulated by 1-3/1-6 β -glucan from medicinal mushrooms Hericium erinaceus and Ganoderma lucidum;Advances in Natural Sciences: Nanoscience and Nanotechnology;2016-11-04

2. The pharmacists’ role in clinical research;Farmacia Hospitalaria;2011-11

3. Overview of Phase I Trials;Handbook of Statistics in Clinical Oncology, Second Edition;2005-12

4. P-813 Lung cancer patients' experiences of phase III clinical trialparticipation;Lung Cancer;2005-07

5. Drug Development in Europe;Anticancer Drug Development Guide;2004